Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients

British Journal of Haematology, 01/21/2011

First–line hydroxyurea (HU) can attain partial molecular response (PMR) in more than 50% of newly diagnosed polycythaemia vera (PV) and essential thrombocythaemia (ET)patients, with a continuous decrease of the JAK2 V617F allele burden in PV patients during treatment.

Print Article Summary Cat 2 CME Report